Clinical Trials for Pancreas Cancer

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls patients with inoperable, advanced, somatostatin receptor–positive, grade 1–2 gastroenteropancreatic neuroendocrine tumors that have progressed after 177Lu-labeled somatostatin-analogue therapy. It compares RYZ101, an investigational 225Ac-DOTATATE radiopharmaceutical that targets somatostatin receptor 2 to deliver alpha radiation, with investigator-selected everolimus, sunitinib, octreotide, or lanreotide.

ClinicalTrials.gov ID: NCT05477576

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN18.2-positive, unresectable advanced or metastatic gastric/gastroesophageal, pancreatic, or biliary tract adenocarcinoma receive AZD0901 (sonesitatug vedotin), a CLDN18.2-targeted antibody–drug conjugate carrying a microtubule-disrupting payload. It is given alone for gastric/gastroesophageal and biliary tract cancer, and with chemotherapy for pancreatic cancer; prior-treatment requirements vary by tumor type.

ClinicalTrials.gov ID: NCT06219941

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic pancreatic adenocarcinoma that progressed during or after one gemcitabine-based regimen, ECOG 0–1, and adequate organ function are randomized to intravenous glufosfamide or weekly bolus 5-FU. Glufosfamide is an investigational glucose-linked alkylating agent designed for uptake through glucose transport pathways and to cause DNA crosslinks.

ClinicalTrials.gov ID: NCT01954992

A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced unresectable or metastatic pancreatic adenocarcinoma, measurable disease, and ECOG performance status 0–1 are randomized to mFOLFIRINOX alone or with intravenous OT-101. OT-101 is an investigational antisense oligonucleotide designed to reduce TGF-β2 production by targeting its mRNA.

ClinicalTrials.gov ID: NCT06079346

IGNITE: A Phase 2 Study of Maintenance Combinatorial Myeloid Immunotherapy in Patients With Unresectable Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or locally advanced unresectable PDAC and a partial response or stable disease after 16–24 weeks of first-line chemotherapy receive maintenance odetiglucan, an investigational β-glucan intended to stimulate innate immunity, plus mitazalimab, an investigational CD40 agonist.

ClinicalTrials.gov ID: NCT07199764

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling fit adults (ECOG 0–1) with previously untreated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. Patients are randomized to first-line mFOLFIRINOX or NALIRIFOX plus setidegrasib/ASP3082, an IV KRAS G12D-targeted protein degrader, versus placebo plus the same chemotherapy backbone.

ClinicalTrials.gov ID: NCT07409272

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic KRAS G12D-mutated pancreatic ductal adenocarcinoma and ECOG 0–1 receive oral VS-7375, an investigational inhibitor of active and inactive KRAS G12D, alone or with the EGFR antibody cetuximab. Combination cohorts enroll patients in the first-line setting or after one prior metastatic regimen.

ClinicalTrials.gov ID: NCT07644559

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent advanced or metastatic breast, ovarian, castration-resistant prostate, or pancreatic cancer harboring selected deleterious HRR gene mutations receive oral EIK1004 (IMP1707) monotherapy. EIK1004 is an investigational PARP1-selective inhibitor designed to impair DNA repair and trap PARP1 on DNA while largely sparing PARP2.

ClinicalTrials.gov ID: NCT06907043

A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with medically treated carcinoid syndrome due to locally advanced or metastatic well-differentiated neuroendocrine tumors, without significant recent progression, are randomized to oral paltusotine 80 mg daily or placebo. Paltusotine is a somatostatin receptor type 2 agonist intended to suppress hormone secretion and reduce symptoms.

ClinicalTrials.gov ID: NCT07087054

A Phase I/IIa Randomized Clinical Trial to Evaluate the Efficacy of EGFR-targeted, PNU-159682-packaged Nanocells & Glycolipid-Packaged Nanocells in Combination With Gemcitabine & Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with EGFR-expressing metastatic pancreatic ductal adenocarcinoma that progressed during or shortly after first-line FOLFIRINOX or NALIRIFOX receive gemcitabine plus nab-paclitaxel with either investigational nanocells or placebo. The nanocells comprise E-EDV-D682, which targets EGFR to deliver cytotoxic PNU-159682, and EDV-GC, which carries α-galactosylceramide to stimulate an antitumor immune response.

ClinicalTrials.gov ID: NCT07049055